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Abstract  
The majority of men treated for prostate cancer will eventually develop castrate 
resistant disease (CRPC) with metastases (mCRPC). There are several options for 
further treatment: chemotherapy, third-line hormone therapy, radium, immunotherapy 
and palliation.  Current ASCO guidelines for survivors of prostate cancer recommend 
that an individual’s information needs at all stages of disease are assessed, and that 
patients are provided with or referred to the appropriate sources for information and 
support. Earlier reviews have highlighted the dearth of such services and we wished 
to see if the situation had improved more recently. Unfortunately we conclude that 
there is still a lack of good quality congruent information easily accessible specifically 
for men with mCRPC and insufficient data regarding the risks, harms and benefits of 
different management plans. More research providing a clear evidence base about 
treatment consequences using patient reported outcome measures is required. 
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Introduction  
Men with prostate cancer may face multiple treatment choices over the course of 
their illness, dependent on the stage of cancer at the time of diagnosis. Surgical and 
radiotherapy techniques have improved over the past decade and there are more 
drugs available offering prospects for an extended life of good quality. Unfortunately 
for the majority of men, progression to castrate resistant prostate cancer (CRPC) is 
universal [1] and treatments aimed at control of the cancer and amelioration of 
symptoms are required. The most common first line chemotherapy treatment for 
metastatic CRPC (mCRPC) is docetaxel plus prednisone, and more novel agents 
have expanded the treatment options, for example, Sipuleucel-T (an autologous 
cellular immunotherapy), cabazitaxel, enzalutamide and abiraterone [2-4]. All 
treatment choices involve highly complex decision-making processes for both the 
clinician and the patient, especially as discussions occur when the patient is 
understandably anxious, vulnerable and in need of reassurance.    
 
The management of mCRPC involves a multidisciplinary team (MDT) approach, 
involving urologists, oncologists, palliative care and specialist nurses, so provision of 
accurate and consistent information is essential.  When a team provide information 
to patients they need to be aware of the different informational roles played by their 
colleagues to ensure consistency [5]. Although health care professionals (HCPs) are 
the most frequently cited and trusted source of knowledge [6, 7], many patients seek 
additional information through support groups (either face-to-face or via the internet, 
chat rooms, blogs etc.), other web based information and phone-lines run by general 
cancer charities and specific prostate cancer charities [8]. In 2014, Macmillan had 
4,334 requests for information related to prostate cancer, 2065 (31%) of which were 
to do with advanced disease, and fairly even split between patients and someone 
else such as a female family member, seeking that information [personal 
communication, 2015]. Similarly, Prostate Cancer UK had 9,923 contacts to their 
specialist nurses (April 2013-14); 48% of whom were diagnosed men who tended to 
ask about treatment options and side effects, whereas their partners called for 
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information about advanced disease and emotional support [personal 
communication, 2015].  
 
Some Internet resources may contain dubious information about treatments or cures 
that are not applicable or unrealistic.  HCPs treating men with mCRPC often 
supplement/complement their own information giving with that contained in National 
Cancer Charity pamphlets, or Prostate Cancer Charity leaflets that have links to their 
related websites. One interesting study developed a tool to evaluate how well the 
information on 9 breast and 7 prostate cancer charity websites [generated by 
www.google.uk.nhs] satisfied patient information needs [9].  The questions perceived 
as best answered were those concerned with genetic risk, different possible 
treatments and how they work, but overall there were 17 questions not answered 
thoroughly by any website, and areas least discussed were “when and how will I 
know if I have been cured?”, and “how do we know if the treatment is working?”.  
The quality of the information on websites varied also, with Charity based websites 
such as Macmillan rated as performing best for prostate cancer (74%) followed by 
the research sites Cancer Research UK (73%).  
 
Existing appraisals of the information needs, expectations and experiences of 
treatment in men with prostate cancer have all commented on the lack of data for 
men and partners in the later stage of disease [10-11]. A series of studies with men 
with advanced prostate cancer, (the majority of whom were castrate resistant), their 
partners and health professionals identified three areas that needed attention [12-
14]. These were a) treatments and associated side effects, b) progression of the 
disease (prospects for the future; end of life expectations), c) available supportive 
care services (including practical assistance). Many men reported not understanding 
the information given about treatments, how they worked and had difficulty getting 
answers to their questions. This was a fact acknowledged by the HCPs who were 
cognisant that men and their partners required more information about treatment and 
side effects, yet when attempting to address their concerns felt patients had difficulty 
understanding the information provided. Men reported difficulty getting clear details 
about their prognosis or what to expect in the future and thought facts were withheld 
and only provided if they asked. HCPs endorsed this and reported that men 
continually asked questions regarding disease progression, prognosis and their 
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anxieties about the end of life, including becoming a burden. Likewise, partners 
wanted the information but did not know what questions to ask. Discussions around 
these issues can be distressing for both patients and family members making some 
of them avoidant of the subject despite paradoxically needing information and 
support. 
 
Men with mCRPC report significantly poorer quality of life (QoL) than other groups of 
men with prostate cancer with priority areas being fatigue, pain, and decreased 
physical activity [15], yet there are few patient reported quality of life data about the 
available treatments. Certain side effects may have far more relevance to the 
decision making process of men than is realised, for example what may be termed 
relatively minor symptoms by a clinician may in fact have a profound effect on certain 
individuals and strongly influence their treatment choices [16]. The American Society 
of Cancer Oncology (ASCO) and its European counterpart (ESMO) have published 
papers recently suggesting that new scales are needed to determine the magnitude 
of clinical benefit from a patient’s perspective [17, 18].  
 
The management options for men with mCRPC have changed with the advent of 
new therapies and the timing of treatments. Whilst this is all good news, there is still 
a lack of documented evidence on the effect disease and treatments have on 
patients’ and families’ overall quality of life and specific symptoms. More research is 
warranted in order to understand the impact of new treatments, physically and 
psychologically for this underserved population. 
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